KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $789000.0.

  • Rigel Pharmaceuticals' Change in Accured Expenses fell 8851.36% to $789000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 12102.67%. This contributed to the annual value of $5.0 million for FY2024, which is 53397.05% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Change in Accured Expenses of $789000.0 as of Q3 2025, which was down 8851.36% from $1.9 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Change in Accured Expenses high stood at $57.9 million for Q1 2021, and its period low was -$59.7 million during Q2 2021.
  • Its 5-year average for Change in Accured Expenses is -$55210.5, with a median of $672000.0 in 2023.
  • Over the last 5 years, Rigel Pharmaceuticals' Change in Accured Expenses had its largest YoY gain of 184818.84% in 2021, and its largest YoY loss of 344423.29% in 2021.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Change in Accured Expenses stood at -$1.5 million in 2021, then tumbled by 78.91% to -$2.6 million in 2022, then skyrocketed by 111.6% to $304000.0 in 2023, then skyrocketed by 41.12% to $429000.0 in 2024, then soared by 83.92% to $789000.0 in 2025.
  • Its last three reported values are $789000.0 in Q3 2025, $1.9 million for Q2 2025, and -$4.1 million during Q1 2025.